以MIB-1评估增殖指数作为宫颈癌放射治疗的预后因素

Assessment of proliferation index with MIB-1 as a prognostic factor in radiation therapy for cervical cancer.

作者信息

Suzuki M, Tsukagoshi S, Saga Y, Ohwada M, Sato I

机构信息

Department of Obstetrics and Gynecology, Jichi Medical School, 3311 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan.

出版信息

Gynecol Oncol. 2000 Nov;79(2):300-4. doi: 10.1006/gyno.2000.5950.

DOI:10.1006/gyno.2000.5950

PMID:11063661

Abstract

OBJECTIVES

The relationship between the expression of murine monoclonal antibody MIB-1, which reacts with Ki-67 nuclear antigen, a marker for proliferating cells, and the prognosis of stage IIIb cervical cancer after radiation therapy was analyzed.

METHODS

A total of 67 patients with stage IIIb cervical cancer who had received radiation therapy were included in the retrospective study. The labeled streptavidin-biotin method was used for immunohistochemical staining of the MIB-1 protein.

RESULTS

In 32 patients showing a high MIB-1 index (percentage of cells labeled with MIB-1 >/=26.4%), the cumulative 5- and 8-year survival rates were 75.8 and 61.5%, respectively, significantly better (P < 0.05) than those in 35 patients with a low MIB-1 index (<26.4%) (59.6 and 41.1%, respectively). Serum squamous cell carcinoma antigen levels, an index of the response to radiation therapy, decreased to </=2.0 ng/mL in 100 and 68% of patients in the high and low MIB-1 index groups, respectively (P < 0.05).

CONCLUSION

These results indicate that MIB-1 antigen may be effective in predicting the sensitivity of cervical cancer to radiation therapy and stage IIIb cervical cancer prognosis.

摘要

目的

分析与增殖细胞标志物Ki-67核抗原反应的鼠单克隆抗体MIB-1的表达与IIIb期宫颈癌放疗后预后之间的关系。

方法

本回顾性研究纳入了67例接受放疗的IIIb期宫颈癌患者。采用标记链霉亲和素-生物素法对MIB-1蛋白进行免疫组织化学染色。

结果

在32例MIB-1指数较高（MIB-1标记细胞百分比≥26.4%）的患者中，5年和8年累积生存率分别为75.8%和61.5%，显著高于35例MIB-1指数较低（<26.4%）的患者（分别为59.6%和41.1%）（P<0.05）。作为放疗反应指标的血清鳞状细胞癌抗原水平，在MIB-1指数高、低组患者中分别有100%和68%降至≤2.0 ng/mL（P<0.05）。